Gain Therapeutics (NASDAQ:GANX) Given Buy Rating at HC Wainwright

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 279.15% from the stock’s previous close.

GANX has been the topic of several other research reports. Scotiabank assumed coverage on shares of Gain Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $12.00 price target on the stock. Roth Capital raised Gain Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Finally, Roth Mkm reissued a “buy” rating and issued a $7.00 price target on shares of Gain Therapeutics in a report on Tuesday, December 24th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $8.20.

Gain Therapeutics Trading Down 4.1 %

GANX opened at $2.11 on Monday. The firm’s 50 day moving average is $2.23 and its 200-day moving average is $1.99. Gain Therapeutics has a 52-week low of $0.89 and a 52-week high of $4.63. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $55.97 million, a P/E ratio of -1.92 and a beta of 0.14.

Institutional Investors Weigh In On Gain Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of GANX. Geode Capital Management LLC grew its stake in Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after purchasing an additional 88,236 shares in the last quarter. Benedict Financial Advisors Inc. bought a new position in Gain Therapeutics during the 4th quarter worth approximately $35,000. Sprott Inc. acquired a new position in shares of Gain Therapeutics in the 4th quarter worth approximately $30,000. Jones Financial Companies Lllp increased its holdings in shares of Gain Therapeutics by 83.6% in the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after acquiring an additional 44,750 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Gain Therapeutics during the 4th quarter valued at approximately $198,000. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.